the strongest treatment findings concerned belly fat and child growth
The tests measured different changes in different patients
Belly fat decreased in one illness. Children grew faster with a hormone shortage. Other tests found blood changes. Those results don't promise the same help for you.
The clearest treatment results concern particular illnesses
In HIV patients with abnormal fat buildup, tesamorelin decreased internal belly fat. Children lacking enough growth hormone grew faster with sermorelin. Other human tests mainly checked changes in hormones. Animal and cell work examined muscle and energy use. Those tests didn't all ask the same health question.
For your care, ask whether the trial tested the medicine and illness concerned.
The current tesamorelin U.S. prescription approval covers that specific fat buildup. Sermorelin once had approval for childhood growth. A pharmacy making sermorelin for a person's prescription now follows separate rules. Neither fact proves an adult aging benefit. CJC-1295 has early human blood findings but no drug approval. MOTS-c was mostly given to animals or tested in cells, leaving human benefit from receiving the peptide unproved.
With the first three peptides, growth hormone release increases from the gland. Production of a protein needed for muscle and organ growth increases in the liver. MOTS-c doesn't increase that hormone release. I'd begin with your hoped-for daily improvement, then name the medicine being offered. Did adults with your illness receive that medicine? Approval and sports rules need checking separately. Neither makes every health claim true.
Treatment trials go further than a changed blood reading
| Peptide | How the medicine acts | What was found | What approval means here | What remains unproved for you |
|---|---|---|---|---|
| Tesamorelin | prompts extra release from the gland of its growth hormone. More of a liver protein used for growth is produced. | Internal belly fat fell in treated HIV patients [1][3][5][6]. | U.S. prescription approval covers that particular fat problem [2]. | Ordinary weight loss without that illness, or slower aging. |
| Sermorelin | copies a short active portion of the message that tells the gland to release hormone. | Children grew faster. The related hormone effects are discussed by reviews and published opinions [8][10][11][12]. | Earlier U.S. approval concerned children. A pharmacy making a person's medicine follows separate rules. | The evidence here lacks large trials following adults long enough to prove the health claims. |
| CJC-1295 | Prompts growth hormone release. The long form remains active by joining protein naturally circulating in blood. | Small human tests found higher hormones and some other blood proteins rising or falling [14][15][16]. | Neither form is an approved treatment. | Health gains and risks after years of receiving the peptide. |
| MOTS-c | affects how cells use energy when energy is scarce or damage threatens. | animals received treatment; cells were also examined. Human researchers measured peptide already in blood [17][18][19][20][21]. | No approved medicine use. | Benefits and risks when patients receive this peptide. |
U.S. approval isn't permission in every country. Ask your pharmacist which rules apply locally. Sports drug rules concern competitors covered by those rules, rather than proving a health benefit.
Three raise growth hormone; MOTS-c changes energy use within cells
Growth hormone release increases when the gland responds to tesamorelin, sermorelin or CJC-1295. More of the protein needed for muscle and organ growth is made by the liver. The medicines differ in makeup and length of action. Changes to tesamorelin make the peptide slower to break down. Sermorelin uses a shorter portion of the natural hormone message. CJC-1295 in its long form joins albumin, a protein naturally circulating in blood. That joining happens once the peptide is in blood. Early CJC studies found hormones remaining high while release still came in bursts [15][16].
You may have a hormone rise without the daily improvement you want.
MOTS-c comes from tiny structures that supply energy within your cells. Experiments examined how cells handled energy shortages or possible damage. An enzyme was linked to the muscle findings too. An enzyme helps chemical changes happen in a cell and is made of protein [17][19][21]. Those experiments didn't show a growth hormone rise. The other medicines' results can't prove a MOTS-c treatment benefit.
What did patients notice after receiving treatment? Ask that at your visit. Was walking easier, or recovery quicker? How long were unwanted effects checked? The MOTS-c evidence here doesn't compare people given treatment with people left untreated. The proposed benefit for you remains unproved.
Adult aging claims need more than childhood growth or higher hormones
The clearest adult treatment evidence concerns internal abdominal fat during HIV care. Tesamorelin trials found that fat decreasing. A review combined trials and examined the results together [1][3][5][6]. That finding stays tied to the patients and medicine tested.
Another illness may leave your weight question unanswered.
Children with a growth hormone shortage grew faster in the direct sermorelin trial [12]. Adult claims often rely on a review, a doctor's opinion or tests of a different medicine [8][9][11]. Another published opinion judged the evidence insufficient for routine treatment of aging with these medicines [10]. Opinions don't establish the benefit offered to you.
Hormone levels and additional proteins in blood changed during CJC-1295 studies. Growth hormone was still released in bursts [14][15][16]. The blood results didn't establish better everyday health. MOTS-c treatment tests mostly used cells or animals. Blood measurements in human research were linked to illness later on. The patients received no peptide treatment [17][18][20][21]. Ask whether people felt better after receiving the medicine. Your proposed benefit needs testing, with unwanted effects checked too. How long did researchers follow patients, and did those patients have illnesses like yours?
Pharmacy permission does not establish a new drug approval
The tesamorelin U.S. approval covers abnormal internal fat buildup in HIV patients [2]. The earlier approved sermorelin use was for child growth difficulties. Pharmacies now make sermorelin for a person's prescription under pharmacy rules. That permission isn't a new approval for adult aging. CJC-1295 and MOTS-c don't have approved human uses in the evidence here.
Name the medicine and the intended use when you ask about approval.
A drug approval in one country doesn't answer the rules in another. A pharmacy may be permitted to make a particular prescription without that medicine gaining separate drug approval. A pharmacy checking a medicine doesn't prove that medicine passed every benefit and safety test needed before drug approval.
At the pharmacy, ask what checks were made on your proposed medicine and which checks weren't done. Then ask your pharmacist which benefit and safety tests an approved drug would need. Those are separate questions. Ask your pharmacist to explain the local rules for that prescription. A doctor can discuss what the evidence means for your care.
Sports bans concern what athletes in that competition may take. You can't infer drug approval or health gains from a sports ban. Nor does availability establish the quality of your proposed medicine. The tesamorelin explanation describes the fat findings. Bring the supporting papers to your care discussion so the benefit claimed for you can be checked.
The change you want to notice is a useful starting point at the visit
Fat loss in one illness is the clearest adult finding here. Tesamorelin has a current U.S. prescription use for that problem. Sermorelin has childhood treatment evidence, with weaker support for adult claims. CJC-1295 tests found human blood changes without drug approval. MOTS-c experiments mainly tested cells or animals.
Describe the daily task or symptom you hope treatment would improve.
Your doctor can then ask whether that change was measured with the exact peptide offered. A blood reading may rise while you feel no better. Another medicine's approval can't settle your benefit. Ask which risks remain unknown and what follow-up would require. How often would you need to return for checks? What would the full set of appointments and blood tests cost? Time and cost matter alongside the uncertain benefit.